Proteos

Executive Summary

Proteos is a US-based contract research organization specializing in custom recombinant protein and antibody production services. Founded in 2003 and headquartered in Kalamazoo, Michigan, it operates as a wholly-owned subsidiary of NanoImaging Services. The company offers expression and purification services across mammalian, insect, and bacterial cell systems, catering to research and development applications in the biologics and antibodies sectors. With a focus on high-quality, project-specific deliverables, Proteos serves academic and industrial clients seeking tailored biologics for drug discovery and preclinical studies. As a private entity with no disclosed funding rounds or public valuation, the company maintains a stable niche in the CRO market, but its limited size and lack of recent news suggest modest growth prospects. The parent company, NanoImaging Services, could provide synergies in structural biology applications, though this remains underexploited.

Upcoming Catalysts (preview)

• Q3 2026Announcement of expanded service capabilities (e.g., new expression systems or purification technologies)60% success
• Q4 2026Strategic partnership or contract win with a major pharma or biotech firm40% success
• TBDLaunch of a consortium or collaborative research initiative leveraging NanoImaging Services' expertise30% success